Related Experiment Video

Updated: Jun 17, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Erlotinib

M Steins1, M Thomas, M Geissler

  • 1Clinic for Thoracic Diseases, University of Heidelberg, Amalienstrasse 5, 69126, Heidelberg, Germany. martin.steins@thoraxklinik-heidelberg.de

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|January 15, 2010
PubMed

Insights

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, like erlotinib, show significant efficacy in treating cancers such as non-small cell lung cancer. This review details their clinical applications, effectiveness, and toxicity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The epidermal growth factor receptor (EGFR) is crucial in cancer development, regulating proliferation, migration, and survival.
  • EGFR's tyrosine kinase activity is a key driver of tumor progression and a significant therapeutic target.

Purpose of the Study:

  • To review clinical data on EGFR tyrosine kinase inhibition.
  • To focus on erlotinib's efficacy, toxicity, and predictive markers in non-small cell lung cancer and pancreatic cancer.

Main Methods:

  • Review of clinical trial data for EGFR tyrosine kinase inhibitors.
  • Emphasis on erlotinib in non-small cell lung cancer (NSCLC) and pancreatic cancer.
  • Analysis of clinical applications, efficacy, toxicity, and response markers.

Main Results:

  • EGFR tyrosine kinase inhibitors have demonstrated significant efficacy in clinical applications.
  • Erlotinib shows promise in treating specific tumor types, with varying responses.
  • Predictive markers are essential for optimizing treatment outcomes.

Conclusions:

  • EGFR tyrosine kinase inhibition is a validated therapeutic strategy for certain cancers.
  • Erlotinib is an important treatment option, particularly for NSCLC and pancreatic cancer.
  • Further research into predictive markers will enhance personalized treatment approaches.

More Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...